HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity

The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: WILFRED A. JEFFRIES, ROBYN P. SEIPP, RAYSHAD GOPAUL, JENNIFER HARTIKAINEN, MURIEL D. DAVID, ALVERINA F. SETIADI
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator WILFRED A. JEFFRIES
ROBYN P. SEIPP
RAYSHAD GOPAUL
JENNIFER HARTIKAINEN
MURIEL D. DAVID
ALVERINA F. SETIADI
description The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor, such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells to enhance their destruction by cytotoxic lymphocytes.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2008207317A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2008207317A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2008207317A13</originalsourceid><addsrcrecordid>eNqNzbEKwjAQxvEuDqK-w4GzkLZDXYMofYDqWkK81oMmF3LXoW9vBd2dPvjzg29bPFrbgfOoy-SUOELKHFgxC7j4hFlQgAfwHBILfYSAvjDjGumnKY5AIcyRR4zkSZd9sRncJHj47q443q7dpT1h4h4lrY8Rtbf3yphzZZq6bGxZ_6feVJI7MQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity</title><source>esp@cenet</source><creator>WILFRED A. JEFFRIES ; ROBYN P. SEIPP ; RAYSHAD GOPAUL ; JENNIFER HARTIKAINEN ; MURIEL D. DAVID ; ALVERINA F. SETIADI</creator><creatorcontrib>WILFRED A. JEFFRIES ; ROBYN P. SEIPP ; RAYSHAD GOPAUL ; JENNIFER HARTIKAINEN ; MURIEL D. DAVID ; ALVERINA F. SETIADI</creatorcontrib><description>The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor, such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells to enhance their destruction by cytotoxic lymphocytes.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2008</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20080724&amp;DB=EPODOC&amp;CC=AU&amp;NR=2008207317A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20080724&amp;DB=EPODOC&amp;CC=AU&amp;NR=2008207317A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WILFRED A. JEFFRIES</creatorcontrib><creatorcontrib>ROBYN P. SEIPP</creatorcontrib><creatorcontrib>RAYSHAD GOPAUL</creatorcontrib><creatorcontrib>JENNIFER HARTIKAINEN</creatorcontrib><creatorcontrib>MURIEL D. DAVID</creatorcontrib><creatorcontrib>ALVERINA F. SETIADI</creatorcontrib><title>HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity</title><description>The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor, such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells to enhance their destruction by cytotoxic lymphocytes.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2008</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzbEKwjAQxvEuDqK-w4GzkLZDXYMofYDqWkK81oMmF3LXoW9vBd2dPvjzg29bPFrbgfOoy-SUOELKHFgxC7j4hFlQgAfwHBILfYSAvjDjGumnKY5AIcyRR4zkSZd9sRncJHj47q443q7dpT1h4h4lrY8Rtbf3yphzZZq6bGxZ_6feVJI7MQ</recordid><startdate>20080724</startdate><enddate>20080724</enddate><creator>WILFRED A. JEFFRIES</creator><creator>ROBYN P. SEIPP</creator><creator>RAYSHAD GOPAUL</creator><creator>JENNIFER HARTIKAINEN</creator><creator>MURIEL D. DAVID</creator><creator>ALVERINA F. SETIADI</creator><scope>EVB</scope></search><sort><creationdate>20080724</creationdate><title>HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity</title><author>WILFRED A. JEFFRIES ; ROBYN P. SEIPP ; RAYSHAD GOPAUL ; JENNIFER HARTIKAINEN ; MURIEL D. DAVID ; ALVERINA F. SETIADI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2008207317A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2008</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>WILFRED A. JEFFRIES</creatorcontrib><creatorcontrib>ROBYN P. SEIPP</creatorcontrib><creatorcontrib>RAYSHAD GOPAUL</creatorcontrib><creatorcontrib>JENNIFER HARTIKAINEN</creatorcontrib><creatorcontrib>MURIEL D. DAVID</creatorcontrib><creatorcontrib>ALVERINA F. SETIADI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WILFRED A. JEFFRIES</au><au>ROBYN P. SEIPP</au><au>RAYSHAD GOPAUL</au><au>JENNIFER HARTIKAINEN</au><au>MURIEL D. DAVID</au><au>ALVERINA F. SETIADI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity</title><date>2008-07-24</date><risdate>2008</risdate><abstract>The invention provides processes and compositions for enhancing the immunogenicity of TAP-1 expression-deficient cells by increasing the presentation of MHC Class I surface molecules for detection by cytotoxic T-lymphocyte cells through increased TAP-1 expression, which comprises administering to the TAP-1 expression-deficient cells a TAP-1 expression increasing amount of a bio-acceptable substance that promotes transcription of TAP-1 gene in the cells to cause enhanced MHC Class I surface expression of the cells. The bio-acceptable substance may be a histone H3 deacetylase inhibitor, such as trichostatin A, a transcriptional co-activator having intrinsic histone acetyl transferase activity or a histone acetyl transferase comprising at least one member of the CBP/p300 protein family. The process and compositions increase the immunogenicity of the target cells to enhance their destruction by cytotoxic lymphocytes.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2008207317A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title HAT acetylation promoters and uses of compositions thereof in promoting immunogenicity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A28%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WILFRED%20A.%20JEFFRIES&rft.date=2008-07-24&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2008207317A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true